AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

✍ Scribed by Mark D. Black; Rachel J. Stevens; Nancy Rogacki; Robert E. Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B. Varty

• Publisher: Springer
• Year: 2010
• Tongue: English
• Weight: 420 KB
• Volume: 215
• Category: Article
• ISSN: 0033-3158
• DOI: 10.1007/s00213-010-2124-0